The liver and pancreas have a common evolutionary origin and are controlled by common genetic regulatory programs. These organs play a central role in two of the world's most common metabolic diseases, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), as well as autoimmune type 1 diabetes. A deeper understanding of the causal mechanisms of these diseases can open up new therapeutic avenues. The possibility of developing replacement therapies for liver failure, genetic disorders and type 1 diabetes is leading to some of the most impressive advances in the field of cell and organ bioengineering.
The workshop brings together leading researchers to discuss the common evolutionary origins and gene regulatory programs of the liver and pancreas. The aim is to deepen the understanding of the causative mechanisms of diabetes and MASLD and to discuss innovative therapeutic strategies.
